Dabigatran versus warfarin for venous thromboembolism [6]

New England Journal of Medicine

Volumn 362, Issue 11, 2010, Pages 1050-

  Teachey, David T ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; DABIGATRAN ETEXILATE; PYRIDINE DERIVATIVE;

ANTICOAGULATION; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; DRUG COST; ECONOMICS; INTERNATIONAL NORMALIZED RATIO; NOTE;

ANTICOAGULANTS; BENZIMIDAZOLES; DRUG COSTS; HUMANS; INTERNATIONAL NORMALIZED RATIO; PYRIDINES; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 77949623856     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1000696     Document Type: Letter

References (3)

1. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007;167:1414-9.
2. Report on new patented drug - Pradax. Ottawa: Patented Medicine Prices Review Board. (Accessed February 25, 2010, at http://www.pmprb-cepmb.gc.ca/ cmfiles/pradax-e.pdf.)
3. Jonas DE, Bryant Shilliday B, Laundon WR, Pignone M. Patient time requirements of anticoagulation therapy with warfarin. Med Decis Making 2009 September 22 (Epub ahead of print).